• 1. E3 ligase ligand chemistries: from building blocks to protein degraders
  Izidor Sosi?,Ale?a Bricelj,Christian Steinebach Chem. Soc. Rev. 2022 51 3487
• 2. Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC)
  S. Krajcovicova,R. Jorda,D. Hendrychova,V. Krystof,M. Soural Chem. Commun. 2019 55 929
• 3. Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents
  Anas Ramadan Kotb,Dina A. Bakhotmah,Abdallah E. Abdallah,Hazem Elkady,Mohammed S. Taghour,Ibrahim. H. Eissa,Mohamed Ayman El-Zahabi RSC Adv. 2022 12 33525
• 4. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
  Caroline M. Robb,Jacob I. Contreras,Smit Kour,Margaret A. Taylor,Mohammad Abid,Yogesh A. Sonawane,Muhammad Zahid,Daryl J. Murry,Amarnath Natarajan,Sandeep Rana Chem. Commun. 2017 53 7577
• 5. [11C]/(13C)Carbon monoxide in palladium-mediated synthesis of imides
  Farhad Karimi,Tor Kihlberg,Bengt L?ngstr?m J. Chem. Soc. Perkin Trans. 1 2001 1528

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to 3-Aminopiperidine-2,6-dione hydrochloride (CAS No: 24666-56-6)

3-Aminopiperidine-2,6-dione hydrochloride, identified by its Chemical Abstracts Service (CAS) number 24666-56-6, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic amine derivative has garnered attention due to its versatile structural framework and potential applications in drug development. The compound’s molecular structure, featuring a piperidine ring substituted with amino and carbonyl functionalities, positions it as a valuable intermediate in synthesizing various bioactive molecules.

The chemical properties of 3-Aminopiperidine-2,6-dione hydrochloride make it particularly interesting for medicinal chemists. The presence of both amino and carbonyl groups allows for diverse functionalization, enabling the creation of complex derivatives with tailored biological activities. This flexibility is crucial in the design of novel therapeutic agents targeting a wide range of diseases.

In recent years, there has been a surge in research focusing on piperidine derivatives due to their demonstrated efficacy in modulating biological pathways. Studies have highlighted the role of piperidine-based compounds in the treatment of neurological disorders, infectious diseases, and cancer. Among these, 3-Aminopiperidine-2,6-dione hydrochloride has emerged as a promising scaffold for further exploration.

One of the most compelling aspects of 3-Aminopiperidine-2,6-dione hydrochloride is its potential in the development of kinase inhibitors. Kinases are enzymes that play a critical role in cell signaling pathways, and their dysregulation is often associated with various diseases, particularly cancer. By designing molecules that selectively inhibit specific kinases, researchers aim to develop treatments that can precisely target pathological processes without affecting normal cellular functions.

Recent advancements in computational chemistry have facilitated the rapid screening of large libraries of compounds for kinase inhibition. 3-Aminopiperidine-2,6-dione hydrochloride has been identified as a lead compound through virtual screening methods, which predict its binding affinity to target kinases. This computational approach has significantly reduced the time and cost associated with drug discovery, allowing for more efficient identification of potential drug candidates.

Moreover, the hydrochloride salt form of 3-Aminopiperidine-2,6-dione hydrochloride enhances its solubility and bioavailability, making it more suitable for pharmaceutical applications. Solubility is a critical factor in drug formulation, as it determines how well a drug can be absorbed and distributed within the body. Improved solubility often translates to better therapeutic outcomes.

The synthesis of 3-Aminopiperidine-2,6-dione hydrochloride involves multi-step organic reactions that require precise control over reaction conditions. Researchers have developed optimized protocols for its preparation, ensuring high yields and purity. These synthetic methods are essential for producing sufficient quantities of the compound for preclinical and clinical studies.

Preclinical studies have begun to explore the pharmacological properties of 3-Aminopiperidine-2,6-dione hydrochloride in various disease models. Initial findings suggest that it exhibits potent inhibitory activity against certain kinases, with minimal side effects observed at therapeutic doses. These results are encouraging and warrant further investigation into its potential as a lead compound for drug development.

The field of medicinal chemistry is constantly evolving, with new techniques and methodologies being developed to enhance drug discovery processes. The use of 3-Aminopiperidine-2,6-dione hydrochloride as a scaffold exemplifies how traditional organic chemistry principles can be combined with modern computational tools to identify novel therapeutic agents.

In conclusion,3-Aminopiperidine-2,6-dione hydrochloride (CAS No: 24666-56-6) represents a significant advancement in pharmaceutical research. Its unique structural features and potential applications in drug development make it a valuable compound for further study. As research continues to uncover new therapeutic targets and innovative drug design strategies,3-Aminopiperidine-2,6-dione hydrochloride is poised to play a crucial role in the next generation of pharmaceutical innovations.

• 2353-44-8(3-Aminopiperidine-2,6-dione)
• 26081-07-2((S)-3-Aminoazepan-2-one hydrochloride)
• 88763-76-2((R)-3-Aminopiperidine-2-one)
• 1892-22-4(3-Aminopiperidin-2-one)
• 34294-79-6((s)-3-Aminopiperidin-2-one)
• 29426-64-0(3-Aminoazepan-2-one hydrochloride)
• 2686-86-4(3-Aminopiperidine-2,6-dione hydrochloride)
• 406216-02-2((3R)-3-aminopiperidin-2-one hydrochloride)
• 90802-45-2(3-Aminopiperidine-2,6-dione hydrobromide)
• 26081-03-8((R)-3-Aminoazepan-2-One Hydrochloride)